About us

Advisory Services

The arguments for mergers, acquisition and licensing in the highly-fluid life sciences sectors, has never been greater: Smaller companies are in desperate need of cash and larger companies are in desperate need of new products. Unlike previous generations of this dynamic, the ability for either side to cope with their problems is in serious doubt. Elixir has interactions with a very large number of companies each year and maintains a database of companies and products which, aside from identifying potential sale of licensing candidates, details the very real sensibilities at board and management level which govern the practicalities of deal making.

M&A and Product Licensing

Elixir is able to overlay its understanding of the life sciences sectors and the strategic needs of their constituents onto a solid foundations of transaction-based services. Elixir is able to assist in the origination and completion of transactions with a “Target” that fits with and compliments the Company both strategically and financially. Elixir provides assistance in the following elements:

  • Assist in defining and applying a set of strategic, financial, and scientific criteria to help identify, evaluate and select the optimal Target(s)

  • Assist in conducting strategic, clinical and commercial evaluation of eligible Targets

  • Draft a robust and compelling description of the business case for marketing purposes

  • Assist in conducting Target due diligence, including intellectual property (“IP”), know-how and patents

  • Assist in preparing structured Target evaluation reports and recommendations for discussion and review by the Company's Board and management team

  • Approach and introduction of the Company to the Target

  • Due Diligence assistance in association with the Company's other advisors

  • Assist in negotiating, structuring and completing the Transaction

  • To the extent required, assist in completing a concurrent or post transaction financing

MBOs

While the search for search for acquisition and licensing Targets is likely to intensify, the need for focus and efficiency has also, for the first time, become a principal concern for those in the sector. Consequently, we believe that the coming period will see a greater focus on out licensing of marginal products, sale of non-core businesses and MBOs.

If you would like to talk to Elixir about a specific project, please click on the button below. The most appropriate person will then contact you directly, to discuss your specific needs.